Showing posts with label Antibody Drug Conjugated. Show all posts
Showing posts with label Antibody Drug Conjugated. Show all posts

Thursday, 12 March 2015

Frequently Asked Questions about the Main Functions of Antibodies & How the Work in the Prenatal Stages in the Science of Immunotherapy.

If you want to understand the basic functions of antibodies and how they work and thus used a lot in the field of antibody immunotherapy, then you’ll want to read this Q&A blogpost about its functions and how it works in the prenatal and neonatal stages of human life.
www.gapsos.com

So what is antibody immune-oncology again?
If you can’t find a way to differentiate the host’s cells from the pathogen or foreign body, then you won’t be able to eradicate it, that’s the way the antibodies work, they detect antigen proteins that aren’t natural within the body and either bind to it and attack these cells or inform the immunity to act on its part.

And how do these antibodies function precisely?
Mainly antibodies can be useful in either secreted soluble form where it’s active in finding antigens or in the form of membranes where it transforms to memory cells that can help the immune system in finding a pathogen antigen that it has detected before, more like the different between new detectives and experienced detectives.

And from where are these antibodies produced?
When the B cells are activated they differentiate into plasma cells, then these plasma cells secrete these antibodies or they differentiate into memory cells that we’ve mentioned, that make the immune response to pathogens fast.

Could you tell you more about how a baby is protected from pathogens when he’s still inside his mother and the antibodies role in that?
Mainly this happens through a phenomenon that is called passive immunization that is provided from the mother and is transferred to the fetus in the form of antibodies in its bloodstream and thus based on that they’re considered a part of the humoral immune system.

While when it comes to the endogenous production of antibodies within the fetus, it varies depending on the different types of antibodies.

And what produces these circulating antibodies?
The production of these antibodies is resulted from clonal B cells that specifically respond to a single type of antigen for example a virus capsid protein fragment.

And can you state how these antibodies contribute to the immunity of the host?
Sure it can contribute in three ways: preventing the entrance of pathogens and their damaging effects, stimulation of immune cells that remove or eat the pathogens and lead to the triggering of pathogenic cells destruction through the immunity.

And thus this wraps up our quick Q&A session on antibody functions and its connection to immunotherapy.

Get more information about antibodies, visit www.gapsos.com.

Wednesday, 11 March 2015

Kick away your problems by advanced treatment in lung cancer.



Lung cancer is one of the leading cancers of death among all the cancers worldwide and it is developed through various processes which are involving development of numerous genetic and epigenetic modifications, mainly the inhibition of tumor suppressor pathways and also the activation of growth promoting pathways. Lung cancer is sub-divided in to two categories: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Lung cancer can be easily treated with the help of immunotherapy. There are several immunotherapeutic of monoclonal Antibody Drug Conjugate, kinase inhibitor drugs, and antibody drug conjugates are available for the treatment with strong activity against the tumors. 
www.gapsos.com

American Cancer Society estimates around 221,200 new cases (115,610 males and 105,590 females) and approximately 158,040 deaths (86,380 males and 71,660 females) due to lung cancer in the United States in 2015. Lung cancer is responsible for 27% deaths among all the cancers and it represents 13.5% of all cancer. The age- standardized rate of incidence and mortality rates varies varied between 3-35 per 100,000 in females, and 21-77 per 100,000 in males and 8-19 per 100,000 in females and 32-52 per 100,000 in males. The most common sign and symptoms of lung cancer are persistent cough, chest pain, voice change, hemoptysis, and recurrent pneumonia or bronchitis. The important risk factors of lung cancer are radiation exposure, industrial substances, radon gas, tuberculosis, air pollution, asbestos, genetics, and smoking and smoking tobacco is other important risk factor of lung cancer and around 87% lung cancer occurs in the United States due to smoking. 

The lung cancer can be diagnose through various imaging techniques such as CT scan and other techniques for the diagnosis of lung cancer are sputum cytology and various biopsy test of blood. There are various radiation therapies, surgical operations, and numerous FDA approved chemotherapeutic drugs for the treatment of lung cancer but these therapies are costly and also having various side-effects for the patients during the treatment or after the treatment.

The immunotherapy is single option which is having minor side-effects for the patients because it enhances the immune system and kills the cancerous cells. The monoclonal antibodies, immune combination therapy, kinase inhibitor drugs, and antibody drug conjugates are having various immunotherapeutic which is having high potency to fight against the cancerous cells. The Bevacizumab, Erlotinib, Afatinib, Gefitinib, and Crizotinib are most commonly used for the treatment of lung cancer and several drugs are under clinical trials for FDA approval. These immunotherapeutic indicates the potential of immunotherapy in the treatment of lung cancer against the other treatments.

Tuesday, 3 March 2015

Frequently Asked Questions about Antibodies, the Complement Pathway & Effector Functions Activation in the Field of Antibody Immunotherapy.



If you’re looking for information about antibodies that can help you understand the field of antibody immunotherapy better , then this Q&A blogpost will help answer many of your questions about natural antibodies , and how antibodies lead to the activation of the complement pathway , and the activation of effector functions .
www.gapsos.com


So how does antibody immunotherapy works?

It’s designing antibodies that work on overriding the immune system responses and lead to certain effects that lead to the annihilation of a pathogen or anti-tumor effects and much more.

What are natural antibodies and the difference between the ones we’ve already mentioned?
Natural antibodies are flowing in the bloodstream of a person, but it’s produced without the presence of infections, foreign bodies, vaccinations…etc. . . .
While the ones we mentioned are usually produced due to an immune response.

And what are these antibodies used on?

They can lead to the activation of the complement system to lead to the pathogen’s lysis before the adaptive immune system starts responding.
Here’s another example, when it comes the xenotransplantation of organs which is transplanting cells or organs from one species to another, these antibodies are thought to be part of the resistance.

Alright, can you tell me how the antibodies assist in the activation of the complement system?

Mainly antibodies that bind to the antigens are capable of attracting the 1st components of the complement cascade via their receptors and thus leads to the activation of the complement pathway which is classical.

And how can this result in killing the pathogen that the antibody has bound itself to?

It can actually lead to that through two different ways that we’ll take a look at:

The pathogen like bacteria would be ingested through a process called opsonization through phagocytes as a result of being attracted through specific complement molecules as a result of the attraction of the complement cascade, another way is through the assistance of the antibodies through what is called MAC short for membrane attack complex where the pathogen is killed directly.

And what is the activation of effector functions and how is that related to antibodies?

Antibodies actually have at least two paratope , these paratope are capable of attaching to antigen epitopes , and through that ability the antibody can attach itself to several antigens and then through the coating of the pathogen it’s possible to activate effector functions to be able to attack these cells .

Wednesday, 18 February 2015

Details of Antibody Immunotherapy with chemical environment of Antibodies.

In this blog we are going to take a fine look about the chemical structures of antibodies in basic simplicity to be able to understand how they work with the immune system.
www.gapsos.com

They are mainly made of Y shaped glycoprotein and are a member of the family of immunoglobulin’s (in fact antibodies or immunoglobulin’s are used interchangeably), and they are mainly produced through the plasma cells which the same as white blood cells, their main form when they are produced is the soluble form because they are secreted, and they only change to the membrane bound form when they are in interactions with other proteins.

The antibodies are significant because they happen to be the main way the immune system detects antigen proteins which are present in any form of foreign body that enters the host, and whenever they are present the antibody through a key lock relationship binds to the antigen and either tags it for the immune system to act on it or attack it itself directly. Antibodies can be modified to override immune responses which are the basis of immunotherapy.

These immunoglobulins are mainly made of two sets of chains that form the Y shape that is two large and heavy chains and two small and light chains. Based on the heavy chains they are classified into different types of iso types, mainly these iso types differ to be able to adapt to any type of antigen proteins.

The way the antigen protein is bound to the antibody is through the hyper variable tip of the antibody which fits precisely to the type of antigen present.

And what gives every single antibody a very great form of flexibility is that heavy chain base can be exchanged for another forming a different iso type and thus it can be used for a different form of antigen, this is what makes a single antibody capable of being used throughout the immune system in many places.

Global Allied Pharmaceuticals is providing immunotherapy and immune-oncology services since more than 14 years. Additionally our company accompanies an expert and skilled team of researchers and oncologists which works effectively to meet the unmet meet of medication.
For more details, Contact us at www.gapsos.com.

Thursday, 12 February 2015

Frequently Asked Questions about Antibodies Class Switching in Antibody Immunotherapy Science.

If you’ve been studying antibody immunotherapy and you’ve met several times cases where the antibodies were very flexible and capable of changing into other types of antibody structures with different effector functions. Then this blogpost will cover the most common questions that you might have about how this is possible and what causes it, and what is responsible for making it happen.
www.gapsos.com

So what are antibodies and what are classes?
If you’re not familiar with antibodies they’re made of immunoglobulins or glycoproteins, that are Y-shaped, and they have several regions along with 2 sets of heavy and light chains, each type of these heavy and light chains along with the amino acid numbers that are carried on them forms the structure of these antibodies and thus what each antibody does in terms of its own effector function and detection capabilities.

It should be noted also that the main type of an antibody is either called class or isotype.
And what is class or isotype switching?
It’s a biological process that happens when the activation of B cells occurs and it allows the production of several immunoglobulin types like IgE or IgG, and because their structures change, their functions change.

And why is changing classes is of any value, what’s the point?
Antibodies when encountering different types of antigens and their detection there are some functions needed that aren’t present in the presently available types of antibodies, and thus changing their type’s enables the antibody to adapt its function whenever antigenic challenges present themselves.

And what is the source of these class switching antibodies?
In actuality they’re a result of the progeny of activated B-cells.
And how does class-switching happens?
To be precise, the constant C regions in the heavy chains of these antibodies change from one type to another, which leads to the change of the structure and thus the function.
While when it comes to the variable region, nothing changes in it.

Why it is nothing changes in the variable region?
Because this region is responsible for antigen targeting, and thus if it changes, then the same antigen wouldn’t be targeted.

And what causes these changes to occur, like what is the trigger for this process?
The trigger for this process is actually the Cytokines, and based on the cytokines present in the environment through which the class-switching takes place, determines the types that will result from such switches.

And thus this wraps our brief Q&A about antibody class switching in the science of antibody immunotherapy.

Global Allied Pharmaceuticals (GAP) has more than 14 years of experience in immuno-oncology and immunotherapy field. You can contact us on www.gapsos.com for further information.